Publications

Browse the library of publications below for key research from ADC Therapeutics scientists.

Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma Eppera N, et al. Blood Cancer Journal. Nov 2024

View Publication

Real-world treatment of large B-cell lymphoma with chimeric antigen receptor T-cell therapy after loncastuximab tesirine. Hamadani M, et al. eJHaem. Sep 2024

View Publication

Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase 2 LOTIS-2 study Caimi PF, et al. Haematologica. Aug 2023.

View Publication

Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial Hamadani M, et al. Blood Adv. Jan 2024

View Publication

In relapsed or refractory diffuse large B-cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine Caimi PF, et al. eJHaem. Nov 2023

View Publication

Real-World Evidence of CAR T-cell Therapy in Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Chihara D, et al. Blood. Sep 2023.

View Publication

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial Caimi PF, et al. Lancet Oncol. May 2021.

View Publication

Contact ADC Therapeutics

Submit a Medical Inquiry Reach out to the ADC Therapeutics team with your specific medical inquiry.

Contact Medical Affairs 1-855-690-0340
8:00 AM to 6:00 PM ET

Report Adverse Reactions or Product Complaints

To report suspected adverse events or product complaints, please call us at 1-855-690-0340 and select prompt 1. You may also call the FDA at 1-800-FDA-1088 or report suspected adverse events at www.fda.gov/medwatch.